IL6 and cardiac arrest: A clinical trial (known as the IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest (IMICA) randomized clinical trial) for the effect of an IL-6 receptor antibody (tocilizumab) with the aim of limiting the inflammatory response after out-of-hospital cardiac arrest (OHCA) was published recently [6,7].